Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03059992 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
A Phase 3 study of Invasive Candidiasis and Coccidioidomycosis, sponsored by Scynexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 233
- Enrollment target
- 20
- Study locations
NCT03059992 is a Phase 3 study of Invasive Candidiasis and Coccidioidomycosis that has completed, run by Scynexis. The registered enrollment target is 233 participants, below the 264-participant average among 5 other Invasive Candidiasis trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03059992, a Phase 3 study of Invasive Candidiasis and Coccidioidomycosis, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 233 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
Conditions Studied
Interventions
- DRUG Ibrexafungerp
Study Locations (20)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College - New York
- Stony Brook University Medical Center - Stony Brook
California
- UC Davis Medical Center - Sacramento
- University of California San Francisco - San Francisco
Georgia
- Emory University Hospital Midtown - Atlanta
- Augusta University - Augusta
Michigan
- University of Michigan - Ann Arbor
- Wayne State University - Detroit
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
North Carolina
- Duke University Medical Center - Durham
- Wake Forest Baptist Medical Center - Winston-Salem
Texas
- University of Texas Southwestern Medical Center Dallas - Dallas
- University of Texas Health Science Center at Houston - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2023-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03059992
The ClinicalTrials.gov registry entry for NCT03059992 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 264-participant average among 5 other Invasive Candidiasis trials with a reported enrollment target (12% lower). The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Invasive Candidiasis appearing as the primary indexed condition, and to 1 intervention - of which Ibrexafungerp is the first listed.
NCT03059992 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03059992 about?
NCT03059992 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment". This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
What is the current status of trial NCT03059992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 233 participants. The study started on 2017-04-01. Estimated completion is 2023-08-25.
What conditions does trial NCT03059992 study?
This clinical trial studies the following conditions: Invasive Candidiasis, Coccidioidomycosis, Histoplasmosis, Invasive Pulmonary Aspergillosis, Mucocutaneous Candidiasis.
What interventions are being tested in trial NCT03059992?
The interventions under investigation include: Ibrexafungerp (DRUG).
Who is sponsoring clinical trial NCT03059992?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03059992 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Candidiasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of Uncomplicated Candidemia Therapy Duration in Children
RECRUITING · NA
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
COMPLETED · Phase 2
-
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.